According to Zhitong Finance App News, Kang Feng Bio-B (06922) issued an announcement. The company has recently submitted a filing with the China Securities Regulatory Commission to implement the full circulation of the company's H shares (“China Securities Regulatory Commission Filing”). According to the China Securities Regulatory Commission's filing, the company has applied to the China Securities Regulatory Commission on behalf of several shareholders of the company to convert a total of 29,341,981 shares of the company's unlisted shares held by such shareholders into H shares of the company and list them on the Stock Exchange (“conversion and listing”). The board of directors of the company is pleased to announce that on March 7, 2024, the China Securities Regulatory Commission has issued a filing notice to the company regarding the conversion and listing. According to the filing notice, the China Securities Regulatory Commission filing relating to the conversion and listing has been completed. If the company wishes to continue the conversion and listing after 12 months from the date the filing notice is issued, it must update the filing with the China Securities Regulatory Commission.

As of the date of this announcement, the details of the implementation plan for conversion and listing have not been implemented.